Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Privium Fund Management B.V.

Key Points

• Privium Fund Management cut its Arcutis Biotherapeutics stake by 16.6% in the third quarter, selling 66,174 shares; it retained 333,193 shares worth about $8.8 million.
• Arcutis reported third-quarter EPS of $0.06, missing analyst estimates of $0.18, while revenue of $143.92 million slightly exceeded expectations.
• Analysts maintain a “Moderate Buy” consensus with a $39.75 average price target. The company also raised its 2026 sales guidance and started enrolling patients in a Phase 3 ZORYVE study for atopic dermatitis.

Privium Fund Management B.V. decreased its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 16.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 333,193 shares of the company's stock after selling 66,174 shares during the quarter. Arcutis Biotherapeutics comprises approximately 1.7% of Privium Fund Management B.V.'s portfolio, making the stock its 19th biggest holding. Privium Fund Management B.V. owned about 0.27% of Arcutis Biotherapeutics worth $8,806,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Montanova Capital LLC boosted its position in shares of Arcutis Biotherapeutics by 0.9% during the 2nd quarter. Montanova Capital LLC now owns 12,437,000 shares of the company's stock worth $326,098,000 after purchasing an additional 110,000 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $276,502,000. Bank of America Corp DE purchased a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $78,330,000. Janus Henderson Group PLC increased its holdings in shares of Arcutis Biotherapeutics by 1.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company's stock valued at $43,684,000 after purchasing an additional 24,505 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at about $36,989,000.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock traded down $1.45 during trading hours on Friday, hitting $25.55. The stock had a trading volume of 3,262,254 shares, compared to its average volume of 2,301,266. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. The stock has a market capitalization of $3.21 billion, a price-to-earnings ratio of 121.67 and a beta of 1.66. Arcutis Biotherapeutics, Inc. has a 1-year low of $19.30 and a 1-year high of $34.80. The stock's fifty day moving average is $27.16 and its two-hundred day moving average is $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.12). The firm had revenue of $143.92 million during the quarter, compared to analysts' expectations of $142.59 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. As a group, analysts predict that Arcutis Biotherapeutics, Inc. will post 0.43 earnings per share for the current fiscal year.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, EVP Masaru Matsuda sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $34.32, for a total transaction of $1,372,800.00. Following the completion of the transaction, the executive vice president directly owned 111,289 shares in the company, valued at approximately $3,819,438.48. This trade represents a 26.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Watanabe sold 4,377 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $139,451.22. Following the transaction, the insider owned 712,826 shares of the company's stock, valued at approximately $22,710,636.36. The trade was a 0.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 123,932 shares of company stock worth $3,553,077 in the last 90 days. Insiders own 9.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ARQT shares. Jefferies Financial Group reissued a "buy" rating and set a $39.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, October 8th. Guggenheim upped their target price on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a "buy" rating in a research report on Monday, October 19th. TD Cowen increased their target price on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a "buy" rating in a report on Thursday. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 29th. Finally, Morgan Stanley lifted their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Arcutis Biotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.75.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company's portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis's lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.